The American Association for Clinical Chemistry (AACC) 2025 meeting in Chicago focuses on the latest advancements in clinical integration of AI, medical misinformation, and health risks from plastics, as well as genomics and microbiome medicine for personalized healthcare. Key topics include strategies for combating misinformation, insights into health risks, and the role of genomics in navigating rare diseases in the U.S. presentations emphasize solving “why” behind rare diseases, from 30 million affected individuals, through genomics techniques and global data sharing. Dr. Heidi L. Rehm will discuss how AI can harness genomic data for personalized medicine, while also exploring challenges in implementing 950 AI devices. Dr. Judy Wawira Gichoya will highlight the complex implementation of AI in healthcare, using real-world examples, and suggest steps to integrate AI effectively. Professor Timothy Caulfield will address the need to prevent the spread of misinformation and ethical misunderstandings.
The ADLM 2025 meeting, co-hosted with the Canadian Society of Clinical Chemists, continues to emphasize clinical integration of AI, medical misinformation, and health risks from plastics, combined with genomics and microbiome medicine for personalized healthcare. Dr. Heidi L. Rehm will delve into strategies for identifying the genetic causes of rare diseases, cancer, and other conditions, offering hope for millions in the U.S. She will also discuss global data sharing efforts and the development of potential new treatments. Dr. Gichoya will analyze the challenges in implementing these AI-driven devices, using specific cases to illustrate both successes and setbacks. Professor Caulfield will address cultural and intellectual forces behind misinformation, confronting fake science claims, and proposing actionable steps to combat it. Dr. Jack Gilbert will explore the role of the human microbiome in health, focusing on its impact on various conditions, from allergic reactions to neurological and metabolic disorders.
The meeting underscores the potential of artificial intelligence in enhancing healthcare, highlighting that 950 machine-learning-enabled devices approved by the FDA are all_unique but could have their limits before broader clinical use. Dr. Judy Wawirah will question the practice, raising concerns about whether the FDA’s approval could hinder the integration of AI in healthcare. Professor Caulfield will discuss prevalent falsehoods, challenging myths like fearmongering and cognitive bias, and provide strategies to safeguard scientific findings. Dr. Gilbert will share insights from empowering glyph identification of microbes and their significance in human health, with implications for disease diagnosis and treatment. Both sections will revolve around how AI and genomics are reshaping clinical care and understanding rare diseases in the U.S.